News Releases

Date	Title
Mar 16, 2020	Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results Company on track to complete Vicinium ® BLA submission in the second half of 2020 with potential approval in first half of 2021 New market research supports large commercial opportunity CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted
Feb 25, 2020	Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium® CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2020-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell , President and CEO, will host a conference call on Monday,
Feb 24, 2020	Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium® CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Sesen Bio (Nasdaq: SESN ) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow , chief executive officer of Trevena, Inc., and
Jan 31, 2020	Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that it has granted non-statutory stock options to purchase an aggregate of 85,500